Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Gets CE Mark for Lung Cancer CDx

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has secured CE marking for its HTG EdgeSeq ALKPlus assay EU, clearing the test for sale in the European Union.

The in vitro diagnostic runs on HTG's EdgeSeq next-generation sequencing system and is designed to measure and analyze mRNA ALK gene rearrangements in lung tumor specimens from patients previously diagnosed with non-small cell lung cancer. It can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori (crizotinib).

"We are pleased to add the HTG EdgeSeq ALKPlus assay EU to our diagnostic assay menu in Europe," HTG President and CEO T.J. Johnson said in a statement. "We plan to offer this assay to selected European early adopters as we seek additional regulatory approvals elsewhere."

In January, HTG announced that it had submitted the third of four expected modules for the assay's premarket approval application to the US Food and Drug Administration. The fourth module is expected to be completed this year.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.